KalVista Pharmaceuticals (KALV) Total Current Liabilities (2014 - 2025)

KalVista Pharmaceuticals has disclosed Total Current Liabilities across 12 years of filings, most recently posting $38.4 million for Q3 2025.

• Total Current Liabilities for Q3 2025 came in at $38.4 million, up 71.23% year-over-year; the trailing twelve-month figure through Jul 2025 was $38.4 million (up 71.23% YoY), and the FY2025 annual result was $45.2 million, up 98.04% from the prior year.
• Total Current Liabilities came in at $38.4 million for Q3 2025 at KalVista Pharmaceuticals, down from $45.2 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $45.2 million in Q2 2025 to a low of $6.5 million in Q1 2021.
• The 5-year median for Total Current Liabilities is $14.1 million (2023), against an average of $17.5 million.
• Across the five-year window, Total Current Liabilities sank 33.23% in 2021 and jumped 98.04% in 2025, its largest moves.
• KalVista Pharmaceuticals' Total Current Liabilities stood at $10.1 million in 2021, then rose by 11.92% to $11.3 million in 2022, then soared by 56.81% to $17.8 million in 2023, then jumped by 47.11% to $26.1 million in 2024, then surged by 46.95% to $38.4 million in 2025.
• The last three Total Current Liabilities figures came in at $38.4 million (Q3 2025), $45.2 million (Q2 2025), and $26.1 million (Q4 2024), per Business Quant data.